AVM Biotechnology

AVM Biotechnology is a biotechnology company that is developing and advancing AVM0703, a patent-pending exclusive formulation. Its AVM0703 triggers the production and release of highly active and powerful novel immune cells.

AVM Biotechnology has the mission to develop and deliver treatments that save lives and improve outcomes by unlocking the untapped potential of the body’s own immune system.

AVM Biotechnology was launched by Dr. Theresa Deisher, Ph.D. With over 30 years of successful pharmaceutical research experience and holding over 47 patents, Dr. Deisher leads a team of scientists who are dedicated to changing what a diagnosis of cancer, autoimmunity, or chronic infectious disease means to patients and their loved ones. The company received FDA IND approval to test its lead product AVM0703 for the treatment of lymphoid malignancies. The mechanism of action that makes AVM0703 work against aggressive cancers may also prove effective against COVID-19. To further that research, AVM Biotechnology has received permission to proceed with clinical trials against this virus as well as Influenza virus which also causes deadly ARDS.